NASDAQ: TRDA
Entrada Therapeutics Inc Earnings Dates, Reports, Calls

Entrada Therapeutics earnings were $55.0M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest TRDA earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$14.0M, down 125.5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, TRDA reported annual earnings of -$6.7M, with -92.9% growth.

TRDA past earnings growth

How has TRDA's earnings growth performed historically?

Company
N/A
Industry
20.31%
Market
51.34%
TRDA's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
TRDA's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

TRDA earnings history

Current Revenue
$215.2M
Current Earnings
$55.0M
Current Profit Margin
25.5%

TRDA Return on Equity

Current Company
16.1%
Current Industry
19.9%
Current Market
35%
TRDA's Return on Equity (16.1%)... subscribe to Premium to read more.
High Return on Equity Performance

TRDA Return on Assets

Current Company
10.4%
Current Industry
1.3%
TRDA is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when TRDA announces earnings.

TRDA Return on Capital Employed

Current Company
15.79%
Current Industry
14.3%
TRDA has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TRDA vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
TRDA$79.94M$54.95M-65.20%$1.67
KALV-$155.51M-$156.39MN/A-$3.69
AKBA$12.85M-$45.99MN/A-$0.23
PROK-$40.10M-$45.61MN/A-$0.55
MREON/AN/AN/AN/A

Entrada Therapeutics Earnings Reports & History FAQ

What were Entrada Therapeutics's earnings last quarter?

Entrada Therapeutics (NASDAQ: TRDA) reported Q3 2024 earnings per share (EPS) of -$0.35, up 132.71% year over year. Total TRDA earnings for the quarter were -$14.03 million. In the same quarter last year, Entrada Therapeutics's earnings per share (EPS) was $1.07.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.

Is Entrada Therapeutics profitable or losing money?

As of the last Entrada Therapeutics earnings report, Entrada Therapeutics is currently profitable. Entrada Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2024 was $54.95 million, a 352.42% decrease year over year.

What was TRDA's earnings growth in the past year?

As of Entrada Therapeutics's earnings date in Q1 2025, Entrada Therapeutics's earnings has grown year over year. TRDA earnings in the past year totalled $54.95 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.